Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
The n e w e ng l a n d j o u r na l of m e dic i n e review article Drug Therapy Use of Diuretics in Patients with Hypertension Michael E. Ernst, Pharm.D., and Marvin Moser, M.D. T hiazide diuretics became available in the late 1950s and were the first effective oral antihypertensive agents with an acceptable side-effect profile.1,2 A half-century later, thiazides remain important medications for the treatment of hypertension. These agents reduce blood pressure when administered as monotherapy, enhance the efficacy of other antihypertensive agents, and reduce hypertension-related morbidity and mortality. This review focuses on thiazides, the diuretics most often indicated for long-term therapy for hypertension; loop diuretics and potassium-sparing agents are briefly considered. Cl inic a l Ph a r m ac ol o gy of Thi a zide s Chemistry and Mechanism of Action Diuretic therapy for hypertension originated in 1937 with the discovery that sulfonamides caused acidemia and mild diuresis by inhibiting carbonic anhydrase in the proximal tubule.3,4 Chlorothiazide, a benzothiadiazine derivative, was isolated during a search for more potent inhibitors of carbonic anhydrase5; chlorothiazide was found to be a more effective diuretic and also to unexpectedly increase the excretion of chloride, rather than bicarbonate.6 This effect on excretion eventually led to identification of the upstream portion of the distal convoluted tubule as the major site of action of the thiazides, where they interfere with sodium reabsorption by inhibiting the electroneutral sodium–chloride symporter (Fig. 1).7 Activity against carbonic anhydrase, although maintained by some thiazides, is considered irrelevant to their mechanism of action, since sodium that is rejected proximally is reabsorbed downstream in the renal tubule in the thick ascending limb. Despite structural variation among the different congeners, the term thiazide diuretic includes all diuretics believed to have a primary action in the distal tubule. From the Department of Pharmacy Practice and Science, College of Pharmacy, and Department of Family Medicine, Carver College of Medicine, University of Iowa, Iowa City (M.E.E.); and the Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT (M.M.). Address reprint requests to Dr. Ernst at the Department of Family Medicine, University of Iowa Hospitals and Clinics, 200 Hawkins Dr., 01291-A PFP, Iowa City, IA 52242, or at michael-ernst@ uiowa.edu. This article (10.1056/NEJMra0907219) was updated on November 3, 2010, at NEJM .org. N Engl J Med 2009;361:2153-64. Copyright © 2009 Massachusetts Medical Society. Pharmacokinetics The pharmacokinetic activities of thiazides are not uniform. All are absorbed orally and have volumes of distribution equal to or greater than body weight (Table 1).8-10 Thiazides are extensively bound to plasma proteins, which helps limit their filtration by the glomeruli, in effect trapping the diuretic in the vascular space and allowing for its delivery to secretory sites of the renal proximal tubular cells. Organic anion transporters may also assist by concentrating thiazides in the tubular lumen.11 The onset of action occurs after approximately 2 to 3 hours for most thiazides, with little natriuretic effect beyond 6 hours.12 Their metabolism, bioavailability, and plasma half-lives are variable. The latter two pharmacokinetic features are the most clinically relevant, as they determine the dose and frequency of administra- n engl j med 361;22 nejm.org november 26, 2009 The New England Journal of Medicine Downloaded from nejm.org by ALEXANDRE SIZILIO on October 13, 2013. For personal use only. No other uses without permission. Copyright © 2009 Massachusetts Medical Society. All rights reserved. 2153 The Proximal convoluted tubule (65–70%) n e w e ng l a n d j o u r na l Distal convoluted tubule (5%) Na+ Filtered blood out (efferent arteriole) Glomerulus Cl− Na+ Thiazides Collecting duct (1–2%) Unfiltered blood in (afferent arteriole) NaHCO3 Aldosterone Carbonic anhydrase inhibitors K+ K+-sparing diuretics and mineralocorticoid-receptor antagonists Thick descending limb Renal artery Na+ Na+/K+ 2Cl− Loop diuretics Cortex Medulla Thick ascending limb Kidney of m e dic i n e intake enhances absorption.8,9 Some thiazides undergo extensive metabolism, whereas others are excreted nearly intact in urine. A 50% reduction in hydrochlorothiazide absorption is observed in patients with heart failure. Relatively little else is known about the influence of disease on the pharmacokinetics of thiazides.8 Most thiazides have a half-life of approximately 8 to 12 hours, just permitting effective oncedaily dosing.9 Among thiazides, chlorthalidone is uniquely long-acting, with an elimination halflife of 50 to 60 hours, owing to its large volume of distribution.13 Nearly 99% of chlorthalidone is bound to erythrocyte carbonic anhydrase, and the drug has a stronger inhibitory effect than other thiazides against several catalytically active mammalian isoforms.14,15 The substantial partitioning of chlorthalidone into erythrocytes creates a tissue reservoir that allows the constant seeping of chlorthalidone back into plasma, through which it exerts its therapeutic effect.14 This depot effect of chlorthalidone may be advantageous in patients who occasionally miss doses, and the agent appears to retain measurable efficacy when given less frequently than once daily.16,17 Pharmacodynamics Hemodynamic Effects Renal vein Urine Cortex Medulla Loop of Henle (25%) Figure 1. Sites of Diuretic Action in the Nephron. The percentage of sodium reabsorbed in a given region is indicated in parentheses. “K+ -sparing agents” collectively refers to the epithelial sodiumchannel inhibitors (e.g., amiloride and triamterene) and mineralocorticoidreceptor antagonists (e.g., spironolactone and eplerenone). Sodium is reabsorbed in the distal tubule and collecting ducts through an aldosterone-sensitive sodium channel and by activation of an ATP-dependent sodium–potassium pump. Through both mechanisms, potassium is secreted into the lumen to preserve electroneutrality. Sodium-channel inhibitors preserve potassium by interfering with the sodium–potassium pump, whereas mineralocorticoid-receptor antagonists spare potassium through their inhibitory effect on aldosterone. NaHCO3 denotes sodium bicarbonate. tion. Chlorothiazide is relatively insoluble in lipids, and large doses are required to achieve levels sufficient to reach the site of action. Hydrochlorothiazide has relatively greater bioavailability; approximately 60 to 70% is absorbed, and food 2154 n engl j med 361;22 The hemodynamic effects of thiazides can be separated into short-term and long-term phases (Table 2).18 Initial decreases in blood pressure are attributed to the reductions in extracellular fluid and plasma volumes, leading to depressed cardiac preload and output.19 Dextran administration during this short-term phase will restore plasma volume and blood pressure to pretreatment levels. Counterregulatory activation of the sympathetic nervous system and the renin–angiotensin–aldosterone system induces a transient rise in peripheral vascular resistance, although this is not usually sufficient to negate the blood-pressure reduction.20 Combining a thiazide with an angiotensin-converting–enzyme (ACE) inhibitor or an angiotensin II–receptor blocker (ARB) can oppose this transient rise in resistance and increase the antihypertensive response. The long-term antihypertensive response to thiazides cannot be reliably predicted by the degree of initial reduction in plasma volume, which eventually returns to near-normal levels. Volume expansion due to the use of dextran at this stage no longer restores the blood pressure to pretreatVersion 7 11/06/09 nejm.org COLOR FIGURE Author Ernst Fig # 1 Title Diuretic Use in Hyper. november 26, 2009 ME JL JRI DE The New England Journal of Medicine Artist LAM Downloaded from nejm.org by ALEXANDRE SIZILIO on October 13, 2013. For personal use only. No other uses without permission. AUTHOR PLEASE NOTE: Figure has been redrawn and type has been reset Copyright © 2009 Massachusetts Medical Society. All rights reserved. Please check carefully Issue date 11/26/09 drug ther apy Table 1. Pharmacokinetic Characteristics of the Thiazide Diuretics Approved for Use in the United States.* Diuretic† Thiazide-type Chlorothiazide Hydrochlorothiazide Methychlothiazide Polythiazide Bendroflumethiazide Thiazide-like Chlorthalidone Metolazone Indapamide Relative Carbonic Anhydrase Inhibition‡ Oral Bioavailability Volume of Distribution Protein Binding percent liters per kilogram percent ++ + — + 0 15–30 60–70 — — 90 1 2.5 — — 1.0–1.5 70 40 — — 94 100% Renal 95% Renal Hepatically metabolized 25% Renal 30% Renal 1.5–2.5 9–10 — 26 9 +++ + ++ 65 65 93 3–13 113 (total)§ 25 (total)§ 99 95 75 65% Renal 80% Renal Hepatically metabolized 50–60 8–14 14 Route of Elimination Elimination Half-Life hr *All the diuretics listed are available in generic form in the United States as monotherapy, except polythiazide (not currently available) and bendroflumethiazide (available only in combination with nadolol). Dashes indicate an absence of data. †The terms thiazide-type and thiazide-like are used to group thiazides on the basis of the presence of a benzothiadiazine molecular structure. Thiazide-like diuretics lack the benzothiadiazine structure but have a mechanism of action similar to that of thiazide-type diuretics, which have the benzothiadiazine structure. ‡Plus signs indicate inhibition, with greater numbers of plus signs reflecting increased inhibition (lower inhibition constants); the zero indicates an inhibition constant of 0. § The volumes of distribution of metolozone and indapamide are given for the total volume, in liters; data on liters per kilogram were not available. ment levels.21-23 A more likely explanation for the persistent antihypertensive effects of most thia zides is an overall reduction in systemic resistance, although the exact mechanisms are unclear.24 Evidence suggests that chlorthalidone may not lower systemic resistance, even after 8 to 12 months of therapy, indicating that other mechanisms may be responsible.17 It is not yet clear whether thiazides have direct vasodilatory properties or induce a reverse autoregulation phenomenon; they have also been proposed to cause structural membrane changes or altered ion gradients.24 A simpler possibility is that a low level of prolonged diuresis produced by long-term thiazide administration may maintain a nominal state of volume contraction, thereby promoting a downward shift in vascular resistance.12 Thiazides have substantial residual effects after discontinuation. Rapid volume expansion, weight gain, and decreased renin levels occur after stopping thiazides, but blood pressure rises slowly and does not immediately reach pretreatment levels.18,25 With adherence to lifestyle modifications (e.g., weight loss, reduction in sodium and alcohol intake), nearly 70% of patients may not require antihypertensive medications for up to 1 year after long-term thiazide-based therapy is withdrawn.26 Tolerance to Diuretics The use of diuretics elicits both short- and longterm adaptations intended to protect intravascular volume. Short-term tolerance may result from a period of post-dose antinatriuresis triggered by the initial reduction in extracellular fluid volume, corresponding to a decline in the drug level in plasma and tubular fluid to below the diuretic threshold.27 Activation of the renin–angiotensin– aldosterone system and the sympathetic nervous system, as well as suppression of the secretion of atrial natriuretic peptide and renal prostaglandin, also contribute to short-term tolerance.27 Post-dose sodium retention is significantly influenced by dietary sodium intake. Sodium restriction promotes an overall negative sodium balance and enhances the therapeutic response to thiazides, whereas persistently high dietary sodium offsets this effect.28 Long-term diuretic adaptation, or the braking effect, refers to a gradual return of the sodium– chloride balance to an electroneutral level. Persistent volume removal appears to trigger long-term activation of the renin–angiotensin–aldosterone system, increasing circulating angiotensin II levels, which in turn promotes increased proximal sodium reabsorption and limits the overall delivery of sodium to the distal site. Other volume-inde- n engl j med 361;22 nejm.org november 26, 2009 The New England Journal of Medicine Downloaded from nejm.org by ALEXANDRE SIZILIO on October 13, 2013. For personal use only. No other uses without permission. Copyright © 2009 Massachusetts Medical Society. All rights reserved. 2155 The n e w e ng l a n d j o u r na l of m e dic i n e Table 2. Hemodynamic and Physiological Effects after Initiation and Cessation of Diuretic Therapy. Variable Short-Term Phase (first 2–4 wk) Long-Term Phase (mo) Cardiac output Decrease Increase (return to pretreatment level) No change Plasma volume Decrease Increase (near-return to pretreatment level) Increase (possibly exceeding pretreatment level) Plasma renin activity Increase Increase Peripheral resistance Transient increase Gradual decrease Decrease Decrease Blood pressure pendent mechanisms may be involved, including the up-regulation of sodium transporters downstream from the primary site of diuretic action and structural hypertrophy of distal nephron segments.29-31 Tolerance to diuretics can be overcome by administering higher doses or combinations of diuretics. For example, synergistic diuresis occurs when a thiazide is added to loop-diuretic monotherapy in patients with edema.32 Occult volume expansion can be present in patients with resistant hypertension, despite existing diuretic therapy; increasing the dose of diuretics may improve the blood pressure.33 High doses and combinations of diuretics must be used carefully to avoid renal injury and marked electrolyte disturbances. Diur e t ic Ther a py for H y per tensi v e Pat ien t s Many physicians consider thiazides the diuretics of choice for long-term therapy. On average, after adjustment for reductions seen with the use of placebo, thiazides induce a reduction in the systolic and diastolic blood pressures of 10 to 15 mm Hg and 5 to 10 mm Hg, respectively. Hypertension responding preferentially to thiazides is considered to be low-renin or salt-sensitive hypertension. The elderly, blacks, and patients with characteristics associated with high cardiac output (e.g., obesity) tend to have this type of hypertension. Thiazides also correct the hypertension and electrolyte abnormalities associated with pseudohypoaldosteronism type 2 (Gordon’s syndrome), a rare mendelian form of hypertension in which the sodium–chloride symporter is excessively active. Thiazides potentiate other antihypertensive agents 2156 Post-Therapy Period Decrease (return to pretreatment level) Increase (gradual return to pretreatment level) Gradual increase when they are used in combination, often producing an additive decrease in blood pressure. The addition of a thiazide minimizes racial differences usually observed in response to monotherapy with inhibitors of the renin–angiotensin–aldosterone system, and the use of such an inhibitor can lessen the degree of the hypokalemia and the metabolic perturbations that may be evoked by thiazides. The dosing of thiazides has evolved in parallel to our progressive understanding of their mechanism of action and dose–response relationships. Earlier use of high doses was based on the belief that efficacy was directly linked to the amount of renal sodium excretion and reduction in plasma volume; the larger the dose, the greater the assumed reduction in blood pressure. However, thiazides are now used in substantially smaller doses, and the term low-dose thiazide has become synonymous with hydrochlorothiazide at a dose of 12.5 to 25 mg per day (or the equivalent dose of another thiazide). Approximately 50% of patients will respond initially to these low doses. In the Systolic Hypertension in the Elderly Program (SHEP),34 chlorthalidone given at a dose of 12.5 mg per day controlled blood pressure, for several years, in more than 50% of patients. Increasing the dose of hydrochlorothiazide from 12.5 to 25 mg per day may result in a response in an additional 20% (approximately) of patients; at 50 mg per day, 80 to 90% of patients should have measurable decreases in blood pressure.35 Increased electrolyte losses at the higher doses of diuretics may preclude their routine use. For many hypertensive patients, several agents will be needed to achieve desired blood-pressure targets. Combination regimens that include a thiazide can achieve therapeutic synergy while min- n engl j med 361;22 nejm.org november 26, 2009 The New England Journal of Medicine Downloaded from nejm.org by ALEXANDRE SIZILIO on October 13, 2013. For personal use only. No other uses without permission. Copyright © 2009 Massachusetts Medical Society. All rights reserved. drug ther apy imizing adverse effects.36 The lack of appropriate per minute per 1.73 m2 of body-surface area) or diuretic use is often identified as the primary drug- by volume overload (e.g., in congestive heart failrelated cause of resistance to treatment.37 ure or the nephrotic syndrome); in patients with such complications, loop diuretics provide consisDiuretics in Renal Impairment tent natriuresis and diuresis. Furosemide should Thiazides are typically considered ineffective when be administered twice daily, whereas torsemide is the glomerular filtration rate decreases below 30 a longer-acting alternative that may be administo 40 ml per minute per 1.73 m2 of body-surface tered once daily. area, although direct evidence is lacking. Small studies have shown that thiazides can elicit an an- Potassium-Sparing Agents and tihypertensive response in patients with chronic Mineralocorticoid-Receptor Antagonists kidney disease38,39; however, their use in patients Potassium-sparing agents induce only minimal with severe renal impairment remains impracti- natriuresis and are relatively ineffective in lowercal, for two reasons: first, the reduced glomeru- ing blood pressure (Fig. 1). Their primary value is lar filtration rate limits the overall filtered sodi- their ability to reduce the loss of potassium when um load reaching the distal tubule; and second, they are used with thiazides. They also avert the reabsorption in the distal tubule is only modestly urinary loss of magnesium, which is important, effective as compared with that in the large-capac- since restoration of magnesium balance is necesity, thick ascending limb.12 These features under- sary for optimal correction of diuretic-induced score the rationale for substituting so-called high- hypokalemia. Triamterene is commonly adminceiling diuretics that act more proximally, in the istered with hydrochlorothiazide, although other loop of Henle, in hypertensive patients with renal fixed-dose combinations of thiazides and potasimpairment. sium-sparing agents are available. Amiloride, an Metolazone, a quinazoline derivative, is an ex- epithelial sodium-channel blocker, is reportedly ception among thiazides because it retains its ef- more effective than spironolactone as therapy in ficacy in patients who have renal insufficiency or blacks who have resistance to treatment.42 other diuretic-resistance states.40 Its effect is limThe phenomenon of aldosterone escape, whereited by slow, erratic absorption; the more predict- by aldosterone activity is incompletely suppressed able bioavailability of other thiazides makes them in hypertensive patients who are receiving inhibibetter suited as long-term therapy of hypertension. tors of the renin–angiotensin–aldosterone system, Metolazone should be reserved for use in combi- can lead to increased salt and water retention. nation with loop diuretics in patients with volume Agents that block the effect of aldosterone are useoverload whose fluid and electrolyte balance are ful for treating this retention. Spironolactone, being closely monitored. It is administered daily a nonselective mineralocorticoid-receptor antagofor a short period (3 to 5 days), with administra- nist, is well absorbed and has a long half-life (aption reduced to thrice weekly after this period or proximately 20 hours), attributable to its active after euvolemia is achieved.27 metabolites.43 Spironolactone not only corrects thiazide-induced potassium and magnesium lossLoop Diuretics es, but also, in low doses (12.5 to 50 mg per day), Diuretics that act in the loop of Henle can lower provides additive hypotensive effects in patients blood pressure but are less effective in the long who have resistance to treatment.44 Spironolactone term than thiazides.41 Most loop diuretics have a remains effective when renal function is impaired, short duration of action (approximately 6 hours), but patients must be monitored carefully for the resulting in an initial diuresis that is followed development of hyperkalemia. Eplerenone, a newer closely by a period of antinatriuresis lasting up to agent that is more selective for aldosterone than 18 hours per day when the drug is administered for androgen and progesterone receptors, is assoonce daily. A net neutral sodium balance, or even ciated with less gynecomastia and breast tendera positive balance, can occur with the use of loop ness than is found with spironolactone. However, diuretics. These agents are most appropriate for direct comparisons of the efficacies of eplerenone the treatment of hypertension that is complicated and spironolactone in patients with treatmentby a reduced glomerular filtration rate (<30 to 40 ml resistant hypertension are lacking. n engl j med 361;22 nejm.org november 26, 2009 The New England Journal of Medicine Downloaded from nejm.org by ALEXANDRE SIZILIO on October 13, 2013. For personal use only. No other uses without permission. Copyright © 2009 Massachusetts Medical Society. All rights reserved. 2157 The n e w e ng l a n d j o u r na l Diur e t ic s in T r i a l s w i th C a r diova scul a r End P oin t s The efficacy of thiazides in reducing the risk of major cardiovascular events was first established in 1967, in the landmark Veterans Affairs Cooperative Study.45 In the ensuing years, thiazide regimens have proved highly effective in the prevention of stroke, coronary heart disease, and heart failure (see the Supplementary Appendix, available with the full text of this article at NEJM.org). Combined meta-analyses and systematic reviews report that, as compared with placebo, thiazide-based therapy reduces relative rates of heart failure (by 41 to 49%), stroke (by 29 to 38%), coronary heart disease (by 14 to 21%), and death from any cause (by 10 to 11%).46-48 These and other analyses also show that the benefit from thia zides is broadly similar to that from other antihypertensive drugs, with results consistent across age and sex strata.46-51 The largest randomized, blinded study performed to date, the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT),52 compared initial treatment consisting of chlorthalidone, at a dose of 12.5 mg per day, with treatment consisting of amlodipine, lisinopril, or doxazosin. The 42,418 high-risk study participants were 55 years of age or older, and 35% were black. The doxazosin treatment was stopped prematurely owing to a significantly greater incidence of heart failure events than with chlorthalidone. At the end of the study, no significant differences were found between the chlorthalidone group and any other treatment group in the rate of the composite primary end point of fatal coronary heart disease or nonfatal myocardial infarction; however, chlorthalidone was superior with respect to several predefined secondary end points, including heart failure (vs. amlodipine and lisinopril) and stroke (vs. lisinopril). The explanation for these findings may be related to the improved blood-pressure control maintained throughout the study in the patients receiving chlorthalidone as compared with those receiving another treatment. Analyses of data stratified on the basis of race and metabolic status consistently indicate that chlorthalidone, used as initial therapy, was not surpassed by any of the three comparison drugs with regard to antihypertensive efficacy or event-rate reduction.53-57 Although chlorthalidone and hydrochlorothiazide have been commonly used in the United 2158 of m e dic i n e States, other thiazides, such as bendroflumethia zide and indapamide, have also been studied. Recently, the use of a sustained-release indapamidebased regimen as initial therapy led to relative reductions of 39%, 64%, and 21% in the rates of fatal stroke, heart failure, and death, respectively, in patients older than 80 years of age.58 Ther a peu t ic C on t rov er sie s The concept of a class effect among thiazides has been promulgated in the absence of comparative studies. In the United States, this debate largely centers on whether to use hydrochlorothiazide or chlorthalidone.59 Chlorthalidone is frequently suggested for use, since the rate of cardiovascular events has been reduced in every study in which it was used, including at the low doses in the SHEP study and ALLHAT, whereas the effects of other thiazide regimens have been less consistent.60 Trials in which hydrochlorothiazide was associated with favorable reductions in the rate of cardiovascular events have typically used higher doses (between 25 and 50 mg per day) than currently advocated. These dose-based differences are underappreciated, and the perception that thia zides are interchangeable is reinforced by the abundance of fixed-dose combinations containing lowdose hydrochlorothiazide. Two trials of low-dose hydrochlorothiazide in combination with other medications showed less effectiveness as compared with the nonthiazide regimen.61,62 Hydrochlorothiazide and chlorthalidone are often incorrectly described as equipotent.10 However, early trials comparing the two drugs often involved the administration of hydrochlorothia zide twice daily to achieve reductions in blood pressure similar to those effected by chlorthali done.63,64 When evaluated on the basis of the dose required to achieve equivalent reductions in the systolic blood pressure, 24-hour ambulatory blood-pressure monitoring confirmed that chlor thalidone is approximately twice as potent as hydrochlorothiazide.65 These findings may be attributable to the ability, with chlorthalidone therapy, to maintain efficacy throughout the night and reduce the gradual rise in blood pressure that may occur during the interval between daily doses. Whether hydrochlorothiazide and chlorthalidone are interchangeable in reducing the risk of cardiovascular events is questionable. An analysis in the Multiple Risk Factor Intervention Trial n engl j med 361;22 nejm.org november 26, 2009 The New England Journal of Medicine Downloaded from nejm.org by ALEXANDRE SIZILIO on October 13, 2013. For personal use only. No other uses without permission. Copyright © 2009 Massachusetts Medical Society. All rights reserved. drug ther apy (MRFIT) suggested a lower mortality rate in the group randomly assigned to undergo a “special intervention” in clinics predominantly using chlorthalidone than in those predominantly using hydrochlorothiazide, but the assignment to a specific diuretic was not randomized, and the study design precluded an ability to reliably separate diuretic effects from those of the other concurrent interventions.66 Conversely, a meta-analysis that did not include the MRFIT findings has suggested no significant differences between the two agents.67 Optimal Role of Diuretics — Initial or Add-On Therapy? Despite a long, well-established record of efficacy, the role of thiazides in hypertension therapy continues to provoke debate.68 Based on the benefits observed in studies in which thiazides were used as initial therapy in a stepped-care approach, with agents added sequentially, guidelines for hypertension therapy in the United States have advocated thiazides as initial treatment since 1977, when the first Joint National Committee report was issued.69 In contrast, British guidelines recommend diuretics more selectively, such as for use in the elderly and blacks.70 European guidelines endorse several antihypertensive agents, including diuretics, as initial therapy.71 An update from the Joint National Committee is anticipated in the near future. Slightly more than one third of the patients in the United States who are eligible for thiazide therapy actually receive it.72 The reasons for this low rate of use may include the absence of corporate promotion of diuretics and the heavy marketing of newer medications.73 Pleiotropic effects in addition to the blood-pressure–lowering effect have been hypothesized for ACE inhibitors and ARBs but not for thiazides.74 In addition, there is discussion about the importance of adverse electrolyte and metabolic changes in association with thiazides and whether these changes abrogate the overall blood-pressure–lowering benefits of the drugs.75,76 Cumulative evidence from trials suggests that the magnitude of blood-pressure lowering is the most important determinant in reducing the cardiovascular risks associated with hypertension.49 As diuretics are eventually required in many hypertensive patients to achieve blood-pressure goals, debate about their role as initial or add-on therapy may be predominantly academic. S a fe t y a nd A dv er se Effec t s of Thi a zide s Much of the criticism against thiazides is directed toward their adverse-effect profile, but low doses are usually well tolerated and have been shown to improve quality-of-life measures.77 Most complications of thiazide therapy are related to the dose and duration of use (Fig. 2). Thiazides can reduce the excretion of calcium and uric acid and thereby increase their plasma levels, and the drugs increase potassium and magnesium excretion, potentially leading to hypokalemia and hypomagnesemia. On average, measured plasma potassium levels decrease by about 0.3 to 0.4 mmol per liter with typical dosing of thiazide monotherapy,78 but coadministration of an ACE inhibitor or an ARB can reduce the incidence of clinically relevant hypokalemia. In ALLHAT, the average potassium level among patients receiving chlorthalidone decreased from 4.3 mmol per liter to 4.1 mmol per liter over a 4-year period.52 The plasma potassium level should be measured at baseline, before the initiation of thiazide monotherapy; a potassium-sparing agent may be considered if the baseline level is less than 3.8 mmol per liter. Maintaining potassium homeostasis is essential, since epidemiologic evidence implicates hypokalemia in the pathogenesis of thiazide-induced dysglycemia.79 The importance of potassium balance is also emphasized by findings from the SHEP study, in which the rate of coronary events among patients with potassium levels below 3.5 mmol per liter was reduced to a lesser degree than among patients with higher potassium levels.80 Hypokalemia can be managed with the use of a potassium-sparing agent or supplemental potassium chloride. Potassium-sparing agents are preferred because they correct the underlying cause. Dietary salt restriction can also minimize thia zide-induced potassium losses.28 New-onset diabetes has been reported in patients receiving thiazides; however, newly diagnosed diabetes occurs over time in many hypertensive patients, regardless of which class of antihypertensive agent is used. Data suggest that receipt of thiazides, as compared with other antihypertensive agents, over several years may lead to an excess of 3 to 4% of new cases of diabetes.79 In ALLHAT, the rates of fatal and nonfatal myocardial infarction were similar among patients re- n engl j med 361;22 nejm.org november 26, 2009 The New England Journal of Medicine Downloaded from nejm.org by ALEXANDRE SIZILIO on October 13, 2013. For personal use only. No other uses without permission. Copyright © 2009 Massachusetts Medical Society. All rights reserved. 2159 n e w e ng l a n d j o u r na l The of m e dic i n e Increased proximal Na+ reabsorption Increased arterial resistance Possible limitation of blood-pressure lowering Increased proximal Ca++ reabsorption Decreased plasma volume Diuretic Adaptations to diuretics Decreased cardiac output Diuresis Orthostasis Decreased Ca++ clearance Hypomagnesemia Increased distal Ca++ reabsorption Decreased uric acid clearance Hyperuricemia Impaired renal H2O excretion Hyponatremia Decreased renal blood flow Prerenal azotemia Increased activation of RAAS Kaliuresis Hypokalemia ? Impaired insulin resistance Dysglycemia Figure 2. Potential Complications of Diuretics and Their Associated Mechanisms. RAAS denotes the renin–angiotensin–aldosterone system. ceiving chlorthalidone, despite the fact that newly diagnosed diabetes was more frequent in the chlorthalidone group (seen in 11.6% of patients) than in the amlodipine group (9.8%) or the lisinopril group (8.1%).54 To date, no analyses of ALLHAT data have indicated that the development of diabetes obviates the benefit of the thiazide.53-57 Similar findings have been reported in a large meta-analysis and in long-term follow-up data of the SHEP cohort.81-83 Despite these reassurances, newly diagnosed diabetes in patients receiving thiazides remains a potential concern, since the period of monitoring for long- term diabetes-related adverse effects on cardiovascular outcomes may have been too short. Few clinically relevant drug interactions occur with the use of thiazides; most notably, nonsteroidal antiinflammatory drugs diminish the therapeutic effect of thiazides by causing sodium retention. Thiazides can increase serum lipid levels, primarily total cholesterol and low-density lipoprotein cholesterol levels, by approximately 5 to 7% in the first year of therapy.84 A summary of common clinical problems encountered with thiazides, and potential solutions, are detailed in Table 3. COLOR FIGURE Version 4 Author Fig # Title ME 2160 n engl j med 361;22 nejm.org november 26, 2009 DE Artist 10/29/09 Ernst 2 Diuretic Use in Hyper. JL JRI LAM AUTHOR PLEASE NOTE: The New England Journal of Medicine Figure has been redrawn and type has been reset Please check carefully Downloaded from nejm.org by ALEXANDRE SIZILIO on October 13, 2013. For personal use only. No other uses without permission. Issue date 11/26/09 Copyright © 2009 Massachusetts Medical Society. All rights reserved. drug ther apy Table 3. Common Clinical Problems Encountered with Thiazides, and Possible Solutions.* Clinical Problem Possible Solution Attack of acute gouty arthritis Obtain uric acid level, and discontinue thiazide if level is elevated. Recheck level after resolution of the attack, and assess the need for prophylaxis. Use another antihypertensive agent if uricosuric prophylaxis is not tolerated or indicated. Hypokalemia (serum potassium ≤3.5 mmol/liter) Correct hypomagnesemia if present. Add potassium-sparing agent or supplemental potassium chloride. Advise salt restriction. If blood pressure is not controlled, consider adding a RAAS inhibitor.† Increase in serum creatinine from baseline level Assess hydration status and discontinue any concurrent and unnecessary nephrotoxic drugs (e.g., NSAIDs). Recognize that a slight elevation in creatinine may be the result of improved blood-pressure control in patients with microvascular disease, in whom renal function is dependent on blood pressure for adequate perfusion. No apparent response to hydrochlorothiazide at a dose of 25 mg/day Assess lifestyle and advise salt restriction if needed. Consider increase in diuretic dose, switch to longer-acting thiazide such as chlorthalidone, or addition of RAAS inhibitor.† Report of dizziness on standing Check for orthostasis. Reduce diuretic dose if necessary. Assess hydration status, and insure diuretic is administered in the morning. Instruct the patient to stand up slowly. Discovery of asymptomatic hyponatremia Assess concurrent medications (e.g., SSRIs) and determine risks and benefits of continuing thiazide. Evaluate patient for excessive water intake. Thiazide therapy recommended for patient with documented history of allergy to a sulfa antibiotic Sulfa antibiotic allergy is not a contraindication to receiving a thiazide. The risk for cross-sensitivity appears to be more dependent on an underlying propensity for atopy than on any specific cross-reactivity among the classes. If true allergy to thiazide is documented, ethacrynic acid (a non–sulfa-containing loop diuretic) can be used. Report of muscle cramps Check serum potassium level and normalize if low. Consider another diuretic if electrolyte levels are normal. Impaired fasting glucose level or diabetes at baseline Institute appropriate management of cardiovascular risk factors. Thiazide use is not precluded. Development of diabetes during thiazide therapy Institute appropriate management of diabetes and related cardiovascular risk factors. The average excess increase in glucose attributed to thiazide use is approximately 3–5 mg/dl (0.2–0.3 mmol/liter). Thiazides will probably be necessary for achieving blood-pressure targets. The addition of a RAAS inhibitor† should be considered, especially if blood pressure is not controlled. Nocturia or incontinence Avoid thiazide dosing in the afternoon or evening. Limit evening fluid intake. Consider discontinuing thiazide if symptoms are intolerable. Baseline GFR <30–40 ml/min/1.73 m2 of body-surface area Substitute furosemide or torsemide. A practical formula for determining the dose of furosemide, in milligrams to be given twice daily, is as follows: (patient age + blood urea nitrogen level) ÷ 2. Torsemide can be given once daily. Development of sun sensitivity Encourage sunscreen use. * GFR denotes glomerular filtration rate, NSAID nonsteroidal antiinflammatory drug, and SSRI selective serotonin-reuptake inhibitor. † Examples of renin–angiotensin–aldosterone system (RAAS) inhibitors are angiotensin-converting–enzyme inhibitors and angiotensin II–receptor blockers. pharmacologic discoveries have advanced the treatment of any disease in such a profound and enDiuretics are a heterogeneous class of antihyper- during manner. tensive medications that have long demonstrated Dr. Ernst reports receiving advisory fees and consulting fees effectiveness in reducing blood pressure and the from Takeda Pharmaceuticals; and Dr. Moser, advisory fees risk of cardiovascular events. With proper atten- from Takeda Pharmaceuticals and GlaxoSmithKline and lecture fees from Kaiser and the Consortium for Southeastern Hypertion to appropriate selection, dosing, and moni- tension Control. No other potential conflict of interest relevant toring, diuretic-based regimens can greatly improve to this article was reported. the ability to achieve blood-pressure goals. Few C onclusions n engl j med 361;22 nejm.org november 26, 2009 The New England Journal of Medicine Downloaded from nejm.org by ALEXANDRE SIZILIO on October 13, 2013. For personal use only. No other uses without permission. Copyright © 2009 Massachusetts Medical Society. All rights reserved. 2161 The n e w e ng l a n d j o u r na l of m e dic i n e References 1. Freis ED, Wanko A, Wilson IM, Par- rish AE. Treatment of essential hypertension with chlorothiazide (Diuril): its use alone and combined with other antihypertensive agents. J Am Med Assoc 1958;166: 137-40. 2. Moser M, Macaulay AI. Chlorothia zide as an adjunct in the treatment of essential hypertension. Am J Cardiol 1959;3: 214-9. 3. Southworth H. Acidosis associated with the administration of para-aminobenzene-sulfonamide (Prontylin). Proc Soc Exp Biol Med 1937;36:58-61. 4. Strauss MB, Southworth H. Urinary changes due to sulfonamide administration. Bull Johns Hopkins Hosp 1938;63: 41-5. 5. Novello FC, Sprague JM. Benzothiadiazine dioxides as novel diuretics. J Am Chem Soc 1957;79:2028-9. 6. Beyer KH Jr, Baer JE, Russo HF, Noll R. Electrolyte excretion as influenced by chlorothiazide. Science 1958;127:146-7. 7. Ellison DH, Velázquez H, Wright FS. Thiazide-sensitive sodium chloride cotransport in early distal tubule. Am J Physiol 1987;253:F546-F554. 8. Beermann B, Groschinsky-Grind M. Clinical pharmacokinetics of diuretics. Clin Pharmacokinet 1980;5:221-45. 9. Welling PG. Pharmacokinetics of the thiazide diuretics. Biopharm Drug Dispos 1986;7:501-35. 10. Jackson EK. Diuretics. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill, 2006:737-70. 11. Hasannejad H, Takeda M, Taki K, et al. Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther 2004;308:1021-9. 12. Sica DA, Moser M. Diuretic therapy in cardiovascular disease. In Black HR, Elliott WJ, eds. Hypertension: a companion to Braunwald’s heart disease. Philadelphia: W.B. Saunders, 2007. 13. Riess W, Dubach UC, Burckhardt D, Theobald W, Vuillard P, Zimmerli M. Pharmacokinetic studies with chlorthalidone (Hygroton) in man. Eur J Clin Pharmacol 1977;12:375-82. 14. Dieterle W, Wagner J, Faigle JW. Binding of chlorthalidone (Hygroton) to blood components in man. Eur J Clin Pharmacol 1976;10:37-42. 15. Temperini C, Cecchi A, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: sulfonamide diuretics revisited — old leads for new applications? Org Biomol Chem 2008;6:2499-506. 16. Bengtsson C, Johnsson G, Sannerstedt R, Werkö L. Effect of different doses of chlorthalidone on blood pressure, serum potassium, and serum urate. Br Med J 1975;1:197-9. 2162 17. Lund-Johansenn P. Hemodynamic changes in long-term diuretic therapy of essential hypertension: a comparative study of chlorthalidone, polythiazide and hydrochlorothiazide. Acta Med Scand 1970;187: 509-18. 18. Tarazi RC, Dustan HP, Frohlich ED. Long-term thiazide therapy in essential hypertension: evidence for persistent alterations in plasma volume and renin activity. Circulation 1970;41:709-17. 19. Wilson IM, Freis ED. Relationship between plasma and extracellular fluid volume depletion and the antihypertensive effect of chlorothiazide. Circulation 1959; 20:1028-36. 20. Roos JC, Boer P, Koomans HA, Geyskes GG, Dorhout Mees EJ. Haemodynamic and hormonal changes during acute and chronic diuretic treatment in essential hypertension. Eur J Clin Pharmacol 1981;19: 107-12. 21. Gifford RW Jr, Mattox VR, Orvis AL, Sones DA, Rosevear JW. Effect of thiazide diuretics on plasma volume, body electrolytes, and excretion of aldosterone in hypertension. Circulation 1961;24:1197-205. 22. de Carvalho JG, Dunn FG, Lohmöller G, Frohlich ED. Hemodynamic correlates of prolonged thiazide therapy: comparison of responders and nonresponders. Clin Pharmacol Ther 1977;22:875-80. 23. Shah S, Khatri I, Freis ED. Mechanism of antihypertensive effect of thiazide diuretics. Am Heart J 1978;95:611-8. 24. Hughes AD. How do thiazide and thiazide-like diuretics lower blood pressure? J Renin Angiotensin Aldosterone Syst 2004;5:155-60. 25. Finnerty FA Jr. Step-down treatment of mild systemic hypertension. Am J Cardiol 1984;53:1304-7. 26. Stamler R, Stamler J, Grimm R, et al. Nutritional therapy for high blood pressure: final report of a four-year randomized controlled trial — the Hypertension Control Program. JAMA 1987;257:148491. 27. Ellison DH. Diuretic resistance: physiology and therapeutics. Semin Nephrol 1999;19:581-97. 28. Ram CV, Garrett BN, Kaplan NM. Moderate sodium restriction and various diuretics in the treatment of hypertension. Arch Intern Med 1981;141:1015-9. 29. Almeshari K, Ahlstrom NG, Capraro FE, Wilcox CS. A volume-independent component to post-diuretic sodium retention in humans. J Am Soc Nephrol 1993;3: 1878-83. 30. Ellison DH, Velázquez H, Wright FS. Adaptation of the distal convoluted tubule of the rat: structural and functional effects of dietary sodium intake and chronic diuretic infusion. J Clin Invest 1989;83: 113-26. 31. Kim GH. Long-term adaptation of re- nal ion transporters to chronic diuretic treatment. Am J Nephrol 2004;24:595-605. 32. Ellison DH. The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann Intern Med 1991; 114:886-94. 33. Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 2002;39:982-8. 34. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-64. 35. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med 1993;328:914-21. [Erratum, N Engl J Med 1994;330:1689.] 36. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289: 2560-72. [Erratum, JAMA 2003;290:197.] 37. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008;51:1403-19. 38. Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure. J Cardiovasc Pharmacol 1995;26:394-400. 39. Dussol B, Moussi-Frances J, Morange S, Somma-Delpero C, Mundler O, Berland Y. A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension. Nephrol Dial Transplant 2005;20:349-53. 40. Paton RR, Kane RE. Long-term diuretic therapy with metolazone of renal failure and the nephrotic syndrome. J Clin Pharmacol 1977;17:243-51. 41. Finnerty FA Jr, Maxwell MH, Lunn J, Moser M. Long-term effects of furosemide and hydrochlorothiazide in patients with essential hypertension: a two-year comparison of efficacy and safety. Angiology 1977;28:125-33. 42. Saha C, Eckert GJ, Ambrosius WT, et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005;46:481-7. 43. Brater DC. Diuretic therapy. N Engl J Med 1998;339:387-95. 44. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003;16:925-30. n engl j med 361;22 nejm.org november 26, 2009 The New England Journal of Medicine Downloaded from nejm.org by ALEXANDRE SIZILIO on October 13, 2013. For personal use only. No other uses without permission. Copyright © 2009 Massachusetts Medical Society. All rights reserved. drug ther apy 45. Veterans Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967;202:1028-34. 46. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as firstline agents: a network meta-analysis. JAMA 2003;289:2534-44. 47. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: metaanalysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338: b1665. 48. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev 2009;3:CD001841. 49. Turnbull F. Effects of different bloodpressure-lowering regimens on major cardiovascular events: results of prospectivelydesigned overviews of randomised trials. Lancet 2003;362:1527-35. 50. Blood Pressure Lowering Treatment Trialists’ Collaboration. Do men and women respond differently to blood pressurelowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J 2008;29:2669-80. 51. Idem. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008;336:1121-3. 52. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97. [Erratum, JAMA 2003;289:178, 2004;291: 2196.] 53. Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005;165:1401-9. 54. Barzilay JI, Davis BR, Cutler JA, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006; 166:2191-201. 55. Wright JT Jr, Harris-Haywood S, Pressel S, et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2008;168:207-17. 56. Black HR, Davis B, Barzilay J, et al. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2008;31:353-60. 57. Wright JT Jr, Probstfield JL, Cushman WC, et al. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med 2009;169:832-42. 58. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-98. 59. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004;43:4-9. 60. Elliott WJ, Grimm RH Jr. Using diuretics in practice — one opinion. J Clin Hypertens (Greenwich) 2008;10:856-62. 61. Wing LMH, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting–enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-92. 62. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in highrisk patients. N Engl J Med 2008;359:241728. 63. Bowlus WE, Langford HG. A comparison of the antihypertensive effect of chlorthalidone and hydrochlorothiazide. Clin Pharmacol Ther 1964;5:708-11. 64. Finnerty FA Jr. A double-blind study of chlorthalidone and hydrochlorothiazide in an outpatient population of moderate hypertensives. Angiology 1976;27: 738-44. 65. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006;47:352-8. 66. The Multiple Risk Factor Intervention Trial Research Group (MRFIT). Mortality after 10 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation 1990;82:1616-28. 67. Psaty BM, Lumley T, Furberg CD. Meta-analysis of health outcomes of chlort halidone-based vs nonchlorthalidone-based low-dose diuretic therapies. JAMA 2004;292:43-4. 68. Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of beta-blockers and diuretics precludes their use for firstline therapy in hypertension. Circulation 2008;117:2706-15. 69. Report of the Joint National Commit- tee on Detection, Evaluation, and Treatment of High Blood Pressure: a cooperative study. JAMA 1977;237:255-61. 70. National Collaborating Centre for Chronic Conditions. Hypertension: management in adults in primary care: pharmacological update. London: Royal College of Physicians, 2006. 71. Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension. J Hypertens 2007;25:1751-62. [Erratum, J Hypertens 2007;25:2184.] 72. Muntner P, Krousel-Wood M, Hyre AD, et al. Antihypertensive prescriptions for newly treated patients before and after the main Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial results and Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure guidelines. Hypertension 2009;53:617-23. 73. Moser M. Why are physicians not prescribing diuretics more frequently in the management of hypertension? JAMA 1998; 279:1813-6. 74. Zhou MS, Schulman IH, Jaimes EA, Raij L. Thiazide diuretics, endothelial function, and vascular oxidative stress. J Hypertens 2008;26:494-500. 75. McInnes GT, Yeo WW, Ramsay LE, Moser M. Cardiotoxicity and diuretics: much speculation, little substance. J Hypertens 1992;10:317-35. 76. Freis ED. The efficacy and safety of diuretics in treating hypertension. Ann Intern Med 1995;122:223-6. 77. Grimm RH Jr, Grandits GA, Cutler JA, et al. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. Arch Intern Med 1997; 157:638-48. 78. Cushman WC, Khatri I, Materson BJ, et al. Treatment of hypertension in the elderly. III. Response of isolated systolic hypertension to various doses of hydrochlorothiazide: results of a Department of Veterans Affairs cooperative study. Arch Intern Med 1991;151:1954-60. 79. Carter BL, Einhorn PT, Brands M, et al. Thiazide-induced dysglycemia: call for research from a working group from the National Heart, Lung, and Blood Institute. Hypertension 2008;52:30-6. 80. Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000;35:1025-30. 81. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed n engl j med 361;22 nejm.org november 26, 2009 The New England Journal of Medicine Downloaded from nejm.org by ALEXANDRE SIZILIO on October 13, 2013. For personal use only. No other uses without permission. Copyright © 2009 Massachusetts Medical Society. All rights reserved. 2163 drug ther apy overviews of randomized trials. Arch Intern Med 2005;165:1410-9. 82. Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996;276: 1886-92. [Erratum, JAMA 1997;277:1356.] 83. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005;95: 29-35. 84. Savage PJ, Pressel SL, Curb JD, et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. Arch Intern Med 1998;158:741-51. Copyright © 2009 Massachusetts Medical Society. Coyote Bluffs, Arizona 2164 Howie Garber, M.D. n engl j med 361;22 nejm.org november 26, 2009 The New England Journal of Medicine Downloaded from nejm.org by ALEXANDRE SIZILIO on October 13, 2013. For personal use only. No other uses without permission. Copyright © 2009 Massachusetts Medical Society. All rights reserved.